ABOUT US/ Team / Management Team
Manel Cascalló Manel Cascalló, PhD – CEO,
Chief Executive Officer

Dr Cascalló is an expert in oncolytic therapies and gene therapy, a field in which has been involved from his PhD. Author of many original scientific papers and reviews in peer-reviewed journals, he is co-inventor of 5 patents on the use of adenovirus as antitumoral agents. He has been a researcher at the University of Barcelona (Spain), at the MD. Anderson Cancer Center de Houston (Houston, USA), at Merck Farma y Química (Barcelona, Spain), and since 2001 at the Virotherapy Group of the Intitut Català d'Oncologia (ICO) – IDIBELL. During his professional career Dr. Cascalló has always been focused in the development of new biotechnological agents for cancer treatment where he has lead different multidisciplinary teams. He possesses a solid expertise in Regulatory Affairs in Gene Therapy and has acted as Expert for the European Medicines Agencies (EMA). Additionally Dr. Cascalló is Member of the Biosafety Committee at IDIBELL where he is actively involved in the supervision of research protocols and provides advice in biosafety-related issues. Dr. Cascalló has also received formation in the management of Biotechnological Companies by the University of Cambridge (UK), and posseses a solid basis in Executive Management by the internationally recognized IESE Business School.

Emma Blasi Emma Blasi,
Regulatory Affairs Manager.

Chemist. Experienced Regulatory Affairs professional with a background in organic synthesis and research in the medicinal chemistry field. Working in the Biopharmaceutical Industry, Ms.Blasi has specialized in the regulatory strategy involved in the development of Advanced Therapy Medicinal Products (ATMPs, cell-based and gene therapy medicinal products), with solid knowledge of regulatory guidelines and strong expertise in writing and submitting technical documentation to Regulatory Health Authorities. Ms. Blasi has also participated in several meetings with different Regulatory Agencies among Europe. Skilled in dealing with Orphan Drugs and ATMP, she coordinates the activities that take place during the development of VCN Biosciences' investigational medicinal products in coordination with Clinical, CMC and Preclinical Departments.

Carmen Blasco Carmen Blasco, PhD,
Clinical Research Manager.

Dr. Carmen Blasco is an expert pharmacist specialized in hepatic metabolism and a highly experienced professional in the area of Clinical Operations from a wide range of perspectives. With more than 10 years of experience in the field, Dr. Blasco has faced clinical trials since site, CRO and Sponsor point of view. She possesses a wide knowledge in the design and execution of clinical trials in the oncology area and has been involved in clinical monitoring training. Her leadership in clinical operations and interaction with clinical investigators supports her role as responsible for the clinical development of new oncology products. She is responsible for supervising all steps involved in clinical research activities at VCN Biosciences and guarantees the delivery of results at the highest quality standards.

Miriam Bazan-Peregrino Miriam Bazan-Peregrino, PhD,
R&D Manager

Dr. Bazan-Peregrino is an expert in oncolytic virotherapy and gene therapy. She is author of many original scientific papers and reviews in peer-reviewed journals, and has presented her research work in a large number of international conferences. During her doctoral research at the University of Oxford in the UK), she was mainly concerned about genetically modifying oncolytic adenoviruses. As the Bellhouse Research Fellow by Examination in Biomedical Engineering (Magdalen College, University of Oxford), she was interested in enhancing the delivery of oncolytic virotherapy to the tumour with different techniques.  As a Marie Curie Intra-European Research Fellow at IDIBELL, she was also interested in the relationships between oncolytic viruses and immune responses against the tumour. She has also worked at the Catalan Institute of Oncology (ICO). Dr. Bazan-Peregrino joined VCN Biosciences in 2014 as the R&D Manager in order to strategically plan VCN candidates at preclinical level, and manage technical staff and R&D activities.

Raul Alba Raul Alba, PhD,
CMC Manager

Dr. Raul Alba possesses a wide expertise in the field of gene therapy with adenoviruses including its manufacture. During his PhD at the Centre of Animal Biotechnology and Gene Therapy (UAB) he developed novel methods to produce High Capacity Adenoviral vectors. He also developed capsid-modified (liver-detargeted) adenoviral vectors for the treatment of the vascular diseases and studying the mechanisms underlying the adenovirus type 5 infection in vivo as post-doc researcher at the University of Glasgow (Scotland). He also acted as Head of Virology and Molecular Biology Department at Nanotherapix SL generating a combined viral and cell therapy using human blood cells and chimeric adenovirus. Dr. Alba is author of an important number of relevant international publications and patents in the adenovirus field. In 2016, Dr. Raul Alba joined VCN Biosciences as Chemistry, Manufacturing and Controls (CMC) Manager.